Parallel imports and mandatory substitution reform: A kick or a muff for price competition in pharmaceuticals

dc.contributor.author	Köksal, Miyase Yesim
dc.contributor.author	Granlund, David
dc.date.accessioned	2011-05-12T16:05:16Z
dc.date.available	2011-05-12T16:05:16Z
dc.date.issued	2011-04
dc.identifier.issn	1403-2465
dc.identifier.uri	http://hdl.handle.net/2077/25497
dc.description.abstract	What has been the effect of competition from parallel imports on prices of locally-sourced onpatent drugs? Did the 2002 Swedish mandatory substitution reform increase this competition? To answer these questions, we carried out difference-in-differences estimation on monthly data for a panel of all on-patent prescription drugs sold in Sweden during the 40 months from January 2001 through April 2004. On average, facing competition from parallel imports caused a 15-17% fall in price. While the reform increased the effect of competition from parallel imports, it was only by 0.9%. The reform, however, did increase the effect of therapeutic competition by 1.6%.	sv
dc.language.iso	eng	sv
dc.relation.ispartofseries	Working Papers in Economics	sv
dc.relation.ispartofseries	496	sv
dc.subject	parallel imports	sv
dc.subject	pharmaceutical drugs	sv
dc.subject	price competition	sv
dc.subject	reference pricing	sv
dc.subject	therapeutic competition	sv
dc.title	Parallel imports and mandatory substitution reform: A kick or a muff for price competition in pharmaceuticals	sv
dc.type	Text	sv
dc.type.svep	report	sv